लिथियम और सुमाट्रिप्टान और नेप्रोक्सेन का इंटरैक्शन

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.

• Serotonergic Agents: Increased risk of serotonin syndrome when co-administered with lithium.

Serotonergic Drugs Clinical Impact: Concomitant use can precipitate serotonin syndrome.

If serotonin syndrome occurs, consider discontinuation of lithium and/or concomitant serotonergic drugs [see Warnings and Precautions ( 5.6 )] .

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St.

Lithium: Increases lithium plasma levels.

Lithium Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance .

The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%.

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and lithium, monitor patients for signs of lithium toxicity.